Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/225612
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Sunitinib-Containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful In Vivo Anti-Glioblastoma Activity

AutorAlamón, Catalina; Dávila, Belén; García, María Fernanda; Sánchez, Carina; Kovacs, Mariángeles; Trias, Emiliano; Barbeito, Luis; Gabay, Martín; Zeineh, Nidal; Gavish, Moshe; Teixidor, Francesc CSIC ORCID; Viñas, Clara CSIC ORCID; Couto, Marcos; Cerecetto, Hugo
Palabras claveCarborane
FLT3
Sub-G1 arrest
Anti-tumor activity
Fecha de publicación18-nov-2020
EditorMultidisciplinary Digital Publishing Institute
CitaciónCancers 12(11): 3423 (2020)
ResumenMalignant gliomas are the most common malignant and aggressive primary brain tumors in adults, the prognosis being—especially for glioblastomas—extremely poor. There are no effective treatments yet. However, tyrosine kinase receptor (TKR) inhibitors and boron neutron capture therapy (BNCT), together, have been proposed as future therapeutic strategies. In this sense in our ongoing project of developing new anti-glioblastoma drugs, we identified a sunitinib-carborane hybrid agent, <b>1</b>, with both in vitro selective cytotoxicity and excellent BNCT-behavior. Consequently, we studied the ability of compound <b>1</b> to inhibit TKRs, its promotion of cellular death processes, and its effects on the cell cycle. Moreover, we analyzed some relevant drug-like properties of <b>1</b>, i.e., mutagenicity and ability to cross the blood–brain barrier. These results encouraged us to perform an in vivo anti-glioblastoma proof of concept assay. It turned out to be a selective FLT3, KIT, and PDGFR-β inhibitor and increased the apoptotic glioma-cell numbers and arrested sub-G1-phase cell cycle. Its in vivo activity in immunosuppressed mice bearing U87 MG human glioblastoma evidenced excellent anti-tumor behavior.
URIhttp://hdl.handle.net/10261/225612
DOI10.3390/cancers12113423
E-ISSN2072-6694
Identificadoresdoi: 10.3390/cancers12113423
Aparece en las colecciones: (ICMAB) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
cancers-12-03423-v2.pdf5,47 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

10
checked on 19-mar-2024

SCOPUSTM   
Citations

22
checked on 12-mar-2024

WEB OF SCIENCETM
Citations

22
checked on 22-feb-2024

Page view(s)

94
checked on 18-mar-2024

Download(s)

98
checked on 18-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


Este item está licenciado bajo una Licencia Creative Commons Creative Commons